Clinical Trial Update: Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating safety and efficacy of vaniprevir (MK-7009) with pegylated interferon and ribavirin in treatment-experienced hepatitis C patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegylated interferon (pegylated interferon alfa)
• Ribavirin (ribavirin)
• vaniprevir (vaniprevir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2014-09-29